At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
Pemigatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
In Brief
A Phase 2 clinical trial evaluating Pemigatinib for MPN (Myeloproliferative Neoplasms). Completed, enrolled 47 participants across 33 sites in 11 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMPN (Myeloproliferative Neoplasms)
CountriesAustria, Belgium, Canada, France, Germany, Italy, Japan, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartApr 2017
Primary CompletionOct 2024
TodayJul 2026
First PostedJan 5, 2017
Enrollment StartApr 25, 2017
Primary CompletionOct 30, 2024
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 9.5 years ago
Interventions
Pemigatinibdrug
Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy. Participants will receive either the intermittent dose (as written) or continuous dosing.